News
The UICEC renews its participation in the ISCIII Clinical Research Support Platform until 2026
This grant allows the UICEC to remain one of the 27 clinical research support units that make up the ISCIII platform.
Viladecans Contra el Càncer gives 35,000 euros to IDIBELL for research on melanomas, gynecological cancers and nutrition
The association based in the Baix Llobregat has been collaborating with IDIBELL since 2016, collecting funds for cancer research.
The Ministry of Science and Innovation awards €4 million for the Phase 2b clinical trial with a new drug for ischemic stroke
Collaborative success in advancing stroke neuroprotection
Environmental exposures and social determinants are key in patients with pulmonary fibrosis
The renowned Dr. Kerri Johannson, a member of the Snyder Institute for Chronic Diseases at Canada’s University of Calgary, gave an IDIBELL seminar on January 12 at the Bellvitge Campus on the impact of environmental exposures on patients with pulmonary fibrosis.
Scientists present an oncolytic virus targeting NK cells with great antitumor potential
A research group from IDIBELL and ICO have presented an oncolytic virus that stimulates the anti-tumor response of NK cells and helps slow the growth of cancer.
Scientists find a new mechanism that explains the development of vascular malformations
A study published in Circulation offers unprecedented perspectives on the molecular mechanisms that lead to Hereditary Hemorrhagic Telangiectasia
The ”la Caixa” Foundation and Barcelona City Council collaborate with IDIBELL and ICO in an innovative project to fight sedentary lifestyle
It is one of the winning initiatives of the 2023 call for grants, which is the result of a collaboration agreement between the charity institution and the council.
IDIBELL receives FORTALECE grant from the Carlos III Health Institute
The grant, of €2,500,000, will promote the Smart Health Community project
Scientists find how to define targeted therapies in lung cancer thanks to a genetic sequencing platform
The use of this massive genetic sequencing platform could improve patient survival thanks to the detection of therapeutic targets and mutations that predispose to cancer.